 |
'Reading', a painting by Kuroda Seiki
|
Most weekends this blog offers up a few substantial links to relevant HCV information, click here for previous "Weekend Reading" articles.
The 47th European Association for the Study of the Liver - EASL
As the annual meeting ends educational sites related to liver disease and hepatitis begin the process of putting together key data on hepatitis C and treatment.
Viral Ed offers continuing medical education-CME and will bring us an Internet symposium discussing important highlights of the meeting. The program -"The 47th Annual EASL: Advances in Chronic Hepatitis C Management and Treatment" will soon be ready to view, make sure you register for the upcoming 1.5-hour program by clicking here.
As a side note - The 19th Conference on Retroviruses and Opportunistic Infections (CROI) Internet Symposium is also on the site.
Clinical Options is still in the process of putting up slides but 20 capsule summaries are ready to view, click here to register.
Clinical Options is still in the process of putting up slides but 20 capsule summaries are ready to view, click here to register.
Additional coverage on the meeting is available at NATAP, HIV and Hepatitis C, hepmag and articles can be read at Medpage Today, aidsmap, Medscape Medical News and Hepatitis C New Drugs and Liver Health.
New online; Advances in HCV Treatment Volume 20 Issue 1 April/May 2012 - Perspective Advances in the Treatment of Hepatitis C Virus Infection, download PDF here.
Summary
The current era in HCV treatment is reminiscent of the transformation of HIV treatment that occurred in the mid-1990s. With the new HCV treatments, cure and complications occur more frequently. We can make smart applications of the treatments available to us right now in some patients, and we await tomorrow’s treatments for other patients. As with the first wave of HIV medications in the potent antiretroviral era, the new HCV drugs offer huge advantages but also present substantial challenges.
Sadly, as most of you know the experimental hepatitis C drug combination of daclatasvir and GS-7977 we read so much about during the meeting may not be entering into phase III clinical trials. The drug companies Bristol-Myers Squibb-daclatasvir and Gilead-GS-7977 may forgo working together on further development of the two drug combo. This is such a disservice to the 170 million individuals worldwide - 3.2 million people in the US- suffering with hepatitis C. According to the CDC in the US there are an estimated 30,000 new acute infections a year, and 8000-10,000 deaths. This disease has rapidly surpassed HIV as a cause of death in the United States.
Please sign the online petition urging Gilead and BMS to collaborate on the promising experimental treatment for hepatitis C.
This April podcast comes to you from the nationally syndicated public radio program The Health Show on WAMC with host Bob Barrett and guest physician discussing both hepatitis C, treatment and Sjogren’s Syndrome, a disease - although rarely - seen in hepatitis C patients.
New online; Advances in HCV Treatment Volume 20 Issue 1 April/May 2012 - Perspective Advances in the Treatment of Hepatitis C Virus Infection, download PDF here.
Summary
The current era in HCV treatment is reminiscent of the transformation of HIV treatment that occurred in the mid-1990s. With the new HCV treatments, cure and complications occur more frequently. We can make smart applications of the treatments available to us right now in some patients, and we await tomorrow’s treatments for other patients. As with the first wave of HIV medications in the potent antiretroviral era, the new HCV drugs offer huge advantages but also present substantial challenges.
Sadly, as most of you know the experimental hepatitis C drug combination of daclatasvir and GS-7977 we read so much about during the meeting may not be entering into phase III clinical trials. The drug companies Bristol-Myers Squibb-daclatasvir and Gilead-GS-7977 may forgo working together on further development of the two drug combo. This is such a disservice to the 170 million individuals worldwide - 3.2 million people in the US- suffering with hepatitis C. According to the CDC in the US there are an estimated 30,000 new acute infections a year, and 8000-10,000 deaths. This disease has rapidly surpassed HIV as a cause of death in the United States.
Please sign the online petition urging Gilead and BMS to collaborate on the promising experimental treatment for hepatitis C.
This April podcast comes to you from the nationally syndicated public radio program The Health Show on WAMC with host Bob Barrett and guest physician discussing both hepatitis C, treatment and Sjogren’s Syndrome, a disease - although rarely - seen in hepatitis C patients.
Enjoy Your Weekend !
No comments:
Post a Comment